Esperion Therapeutics, Inc. (ESPR)

NASDAQ: ESPR · Real-Time Price · USD
1.820
+0.210 (13.04%)
At close: Oct 2, 2024, 4:00 PM
1.800
-0.020 (-1.10%)
Pre-market: Oct 3, 2024, 4:19 AM EDT
13.04%
Market Cap 357.13M
Revenue (ttm) 277.79M
Net Income (ttm) -98.50M
Shares Out 196.22M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,850,746
Open 1.610
Previous Close 1.610
Day's Range 1.580 - 1.830
52-Week Range 0.700 - 3.400
Beta 1.00
Analysts Buy
Price Target 8.17 (+348.9%)
Earnings Date Nov 5, 2024

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products als... [Read more]

Sector Healthcare
IPO Date Jun 26, 2013
Employees 240
Stock Exchange NASDAQ
Ticker Symbol ESPR
Full Company Profile

Financial Performance

In 2023, Esperion Therapeutics's revenue was $116.33 million, an increase of 54.14% compared to the previous year's $75.48 million. Losses were -$209.25 million, -10.45% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $8.17, which is an increase of 348.90% from the latest price.

Price Target
$8.17
(348.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under ...

7 days ago - GlobeNewsWire

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insur...

4 weeks ago - GlobeNewsWire

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Confer...

5 weeks ago - GlobeNewsWire

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy ra...

6 weeks ago - Seeking Alpha

Esperion Therapeutics: Strategically Positioned To Grow

Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving sign...

6 weeks ago - Seeking Alpha

Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript

Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript

7 weeks ago - Seeking Alpha

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth –

7 weeks ago - GlobeNewsWire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under Espe...

2 months ago - GlobeNewsWire

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) –

2 months ago - GlobeNewsWire

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

– OMERS Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment –

3 months ago - GlobeNewsWire

Esperion to Participate in Upcoming June Investor Conferences

ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, wh...

4 months ago - GlobeNewsWire

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Ja...

4 months ago - GlobeNewsWire

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism...

4 months ago - Seeking Alpha

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for b...

5 months ago - GlobeNewsWire

Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - ...

5 months ago - Seeking Alpha

Esperion Reports First Quarter 2024 Financial Results

– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y ...

5 months ago - GlobeNewsWire

Esperion to Participate in Upcoming May Investor Conferences

ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, ...

5 months ago - GlobeNewsWire

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –

6 months ago - GlobeNewsWire

Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications

Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.

6 months ago - Schwab Network

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m...

6 months ago - GlobeNewsWire

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and C...

6 months ago - GlobeNewsWire

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) --  Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen) ...

6 months ago - GlobeNewsWire

U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic ac...

6 months ago - Business Wire

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes Da...

6 months ago - GlobeNewsWire

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)-Inhibiting Regimen) Outcomes Trial 1 –

6 months ago - GlobeNewsWire